Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 11/20 | 0.56 |
| ▸ | MMP2 | P08253 | 11/20 | 0.56 |
| ▸ | MMP3 | P08254 | 4/20 | 0.56 |
| ▸ | MMP1 | P03956 | 4/20 | 0.56 |
| ▸ | MMP13 | P45452 | 4/20 | 0.56 |
| ▸ | MMP7 | P09237 | 2/20 | 0.56 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.51 |
| ▸ | MMP8 | P22894 | 3/20 | 0.51 |
| ▸ | MMP12 | P39900 | 3/20 | 0.51 |
| ▸ | MMP14 | P50281 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869667 | 1.00 | MMP9 (0.56) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5869499 | 1.00 | MMP9 (0.56) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5869942 | 0.93 | MMP2 (0.54) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5869940 | 0.93 | MMP2 (0.54) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5869954 | 0.93 | MMP2 (0.54) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5870238 | 0.92 | MMP2 (0.53) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5870225 | 0.92 | MMP2 (0.53) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5869949 | 0.92 | MMP2 (0.53) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5869951 | 0.92 | MMP2 (0.53) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL5869945 | 0.92 | MMP2 (0.53) | MMP9MMP2MMP3MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | MMP9 1346/4885MMP2 266/4885MMP3 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.